Oncolytic Virus (OVV-01) Injection in the Treatment of Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2024-02-28
Target enrollment:
Participant gender:
Summary
Phase Ia: To investigate the safety, tolerability and efficacy of OVV-01 injection in the
treatment of patients with advanced solid tumors (OVV-01 single dose gradient exploration).
Phase Ib: To evaluate the safety, tolerability and efficacy of OVV-01 injection combined with
immune checkpoint inhibitors pembrolizumab (anti-PD-1 monoclonal antibody) or atezolizumab
(anti-PD-L1 monoclonal antibody) in the treatment of patients with advanced solid tumors
(OVV-01 combined with PD-1/PD-L1 monoclonal antibody dose gradient exploration);
Phase Ic: A cohort expansion of Phase Ib to further analyze the efficacy and safety of OVV-01
injection combined with immune checkpoint inhibitor injection in the treatment of advanced
solid tumors.